However, some patients still have refractory disease, relapse, sight-threatening eye disease or irreversible organ damage. Recent improvements in the understanding of the pathogenic mechanisms ...

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need ...

The treatment failed to improve the vision-guided mobility of patients with the eye disease X-linked retinitis pigmentosa (XLRP) in a phase 3 trial, according to results shared May 2. The LUMEOS ...

We perceive the world through our eyes. And yet, the eye, too, is vulnerable to cancerous disease. Many eye cancers show signs at early stages and respond well to treatment. A small lump on the ...

A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to ...

Learn about eye changes that could indicate serious health conditions, from blurry vision to persistent floaters and flashes ...

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap Aldeyra Therapeutics, Inc. (Nasdaq: ALDX ...

Dry eye disease is a common inflammatory disease estimated to affect over 39 million adults in the US. It is characterised by insufficient moisture and lubrication in the anterior surface of the ...

The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis. Novartis paid Takeda $3.4 ...

SALT LAKE CITY — Multimodal AI models may be useful to predict glaucomatous status of eyes, according to a poster presentation at the Association for Research in Vision and Ophthalmology meeting ...